×
About 1,240 results

ALLMedicine™ Hairy Cell Leukemia Center

Research & Reviews  373 results

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT01059786

Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and ...

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT00923013

Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL. Patients with the CD25-negative variant (HCLv) respond poorly to initial cladr...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...

see more →

Guidelines  1 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  38 results

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04322383

Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases per year in the US. BRAF V600E mutation is very common in classic HCL. HCL variant (HCLv) is wild type for BRAF an...

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04362865

Jun 24th, 2022 - Background: Patients infected with COVID-19 have an unpredictable risk to worsen and die, making it difficult to decide who can quarantine at home and who should be monitored for respiratory failure as an inpatient. This risk may be related in par...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Jun 24th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT01059786

Jun 24th, 2022 - Background: Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and ...

see more →

News  74 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Dr. Park on Vemurafenib in Hairy Cell Leukemia
https://www.onclive.com/view/dr-park-on-vemurafenib-in-hairy-cell-leukemia

Oct 6th, 2021 - Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia. Park says the first breakthrough in hairy cell leukemia came in the 1980s when physicians learned that ...

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors

Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies
https://www.onclive.com/view/dr-ailawadhi-on-the-efficacy-of-lisaftoclax-in-hematologic-malignancies

Jun 7th, 2021 - Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the activity of lisaftoclax in patients with hematologic malignancies. Lisaftoclax was evaluated ...

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers
https://www.onclive.com/view/lisaftoclax-shows-early-safety-efficacy-in-relapsed-refractory-cll-sll-and-other-hematologic-cancers

Jun 7th, 2021 - The novel BCL-2 inhibitor lisaftoclax (APG-2575) elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and other hematologic cancers, according to data ...

see more →

Patient Education  1 results see all →